12,515 Shares in Kenvue Inc. (NYSE:KVUE) Bought by Kovack Advisors Inc.

Kovack Advisors Inc. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,515 shares of the company’s stock, valued at approximately $267,000.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Huntington National Bank boosted its position in Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after purchasing an additional 871 shares during the period. ING Groep NV boosted its position in Kenvue by 23.6% during the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after purchasing an additional 681,954 shares during the period. Handelsbanken Fonder AB boosted its position in Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after purchasing an additional 21,222 shares during the period. Alberta Investment Management Corp boosted its position in Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after purchasing an additional 109,700 shares during the period. Finally, Longbow Finance SA boosted its position in Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock worth $5,990,000 after purchasing an additional 13,287 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 1.9 %

KVUE opened at $23.58 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a 50-day simple moving average of $21.46 and a 200 day simple moving average of $22.26. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.07 billion, a price-to-earnings ratio of 44.49, a P/E/G ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on KVUE shares. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays reduced their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Citigroup reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $23.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.